参考文献/References:
[1] Lennon VA,Wingerchuk DM,Kryzer TJ,et al.A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis[J].Lancet,2004,364(9451):2106-2112.
[2] Wingerchuk DM,Lennon VA,Lucchinetti CF,et al.The spectrum of neuromyelitis optica[J].The Lancet Neurology,2007,6(9):805-815.
[3] Lennon VA,Kryzer TJ,Pittock SJ,et al.IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water Channel[J].J Exp Med,2005,202(4):473-477.
[4] Jarius S,Wildemann B.AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance[J].Nat Rev Neurol,2010,6(7):383-392.
[5] Wingerchuk DM,Banwell B,Bennett JL,et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J].Neurology,2015,85(2):177-189.
[6] Bizzoco E,Lolli F,Repice AM,et al.Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution[J].J Neurol,2009,256(11):1891-1898.
[7] Wingerchuk DM,Pittock SJ,Lucchinetti CF,et al.A secondary progressive clinical course is uncommon in neuromyelitis optica[J].Neurology,2007,68(8):603-605.
[8] Bichuetti DB,Lobato De Oliveira EM,De Souza NA,et al.Neuromyelitis optica treatment analysis of 36 patients[J].Arch Neurol,2010,67(9):1131-1136.
[9] Costanzi C,Matiello M,Lucchinetti CF,et al.Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica[J].Neurology,2011,77(7):659-666.
[10] Huh SY,Kim SH,Hyun JW,et al.Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder[J].JAMA Neurol,2014,71(11):1372-1378.
[11] Mealy MA,Wingerchuk DM,Palace J,et al.Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy[J].JAMA Neurol,2014,71(3):324-330.
[12] Kim SH,Jeong IH,Hyun JW,et al.Treatment outcomes with rituximab in 100 patients with neuromyelitis optica influence of FCGR3A polymorphisms on the therapeutic response to rituximab[J].JAMA Neurol,2015,72(9):989-995.
[13] Jacob A,Weinshenker BG,Violich I,et al.Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients[J].Arch Neurol,2008,65(11):1443-1448.
[14] Araki M,Matsuoka T,Miyamoto K,et al.Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study[J].Neurology,2014,82(15):1302-1306.
[15] Pittock SJ,Lennon VA,Mckeon A,et al.Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study[J].Lancet Neurol,2013,12(6):554-562.
[16] Uzawa A,Mori M,Hayakawa S,et al.Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis[J].European Journal of Neurology,2010,17(5):672-676.
[17] Shimizu J,Hatanaka Y,Hasegawa M,et al.IFNβ-1b May severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum[J].Neurology,2010,75(16):1423-1427.
[18] Sellner J,Boggild M,Clanet M,et al.EFNS guidelines on diagnosis and management of neuromyelitis optica[J].Eur J Neurol,2010,17(8):1019-1032.
[19] Barnes PJ.Corticosteroids: the drugs to beat[J].Eur J Pharmacol,2006,533(1/3):2-14.
[20] Sato D,Callegaro D,Lana-Peixoto MA,et al.Treatment of neuromyelitis optica: an evidence based review[J].Arq Neuropsiquiatr,2012,70(1):59-66.
[21] Wm C,Fujihara K.Neuromyelitis optica[J].Curr Treat Options Neurol,2010,12(3):244-255.
[22] Watanabe S,Misu T,Miyazawa I,et al.Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis[J].Mult Scler,2007,13(8):968-974.
[23] Wingerchuk DM,Weinshenker BG.Neuromyelitis optica[J].Curr Treat Opti Neurol,2008,10(1):55-66.
[24] 吴萱,林艾羽,王华燕,等.维持性泼尼松治疗视神经脊髓炎的疗效观察[J].中国神经精神疾病杂志,2015,41(3):145-149.
[25] Qiu W,Kermode AG,Li R,et al.Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica[J].J Clin Neurosci,2015,22(7):1178-1182.
[26] Mandler RN,Ahmed W,Dencoff JE.Devic’s neuromyelitis optica:a prospective study of seven patients treated with prednisone and azathioprine[J].Neurology,1998,51(4):1219-1220.
[27] La Mantia L,Mascoli N,Milanese C.Azathioprine. safety profile in multiple sclerosis patients[J].Neurol Sci,2007,28(6):299-303.
[28] 魏红,李成荣,李智毅,等.硫嘌呤甲基转移酶遗传多态性检测在6-MP个体化治疗中的意义[J].中国医院药学杂志,2007,27(1):5-7.
[29] Stojiljkovic M,Patrinos GP,Pavlovic S.Clinical applicability of sequence variations in genes related to drug metabolism[J].Curr Drug Metab,2011,12(5):445-454.
[30] Jacob A,Matiello M,Weinshenker BG,et al.Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients[J].Arch Neurol,2009,66(9):1128-1133.
[31] 李柱一,胡学强,许贤豪,等.中国重症肌无力诊断和治疗指南[J].中华神经科杂志,2015,48(11):934-940.
[32] Jarius S,Aboul-Enein F,Waters P,et al.Antibody to aquaporin-4 in the long-term course of neuromyelitis optica[J].Brain,2008,131(11):3072-3080.
[33] Yaguchi H,Sakushima K,Takahashi I,et al.Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder[J].Internal Medicine,2013,52(9):969-972.
[34] 张遥,费允云,牛婧雯,等.合并结缔组织病的视神经脊髓炎谱系疾病回顾性研究[J].中华医学杂志,2014,94(39):3056-3061.
[35] Torres J,Pruitt A,Balcer L,et al.Analysis of the treatment of neuromyelitis optica[J].J Neurol Sci,2015,351(1/2):31-35.
[36] Ehninger G,Schuler U,Proksch B,et al.Pharmacokinetics and metabolism of mitoxantrone. A review[J].Clin Pharmacokinet,1990,18(5):365-380.
[37] Edan G,Morrissey S,Le Page E.Rationale for the use of mitoxantrone in multiple sclerosis[J].J Neurol Sci,2004,223(1):35-39.
[38] Kim SH,Kim W,Park MS,et al.Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica[J].Arch Neurol,2011,68(4):473-479.
[39] Cabre P,Olindo S,Marignier R,et al.Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study[J].J Neurol Neurosurg Psychiatry,2013,84(5):511-516.
[40] Kitley JL,Leite MI,Matthews LA,et al.Use of mitoxantrone in neuromyelitis optica[J].Arch Neurol,2011,68(8):1086; author reply 1086-7.
[41] Weinstock-Guttman B,Ramanathan M,Lincoff N,et al.Study of mitoxantrone for the treatment of recurrent neuromyelitis optica(Devic disease)[J].Arch Neurol,2006,63(7):957-963.
[42] Gonsette RE.Mitoxantrone immunotherapy in multiple sclerosis[J].Multiple Sclerosis,1996,1(6):329-332.
[43] Kitley J,Elsone L,George J,et al.Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies[J].J Neurol Neurosurg Psychiatry,2013,84(8):918-921.
[44] Ramanathan RS,Malhotra K,Scott T.Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate[J].BMC Neurol,2014,14:51.
[45] Sato D,Callegaro D,Lana-Peixoto MA,et al.Treatment of neuromyelitis optica: an evidence based review[J].Arq Neuropsiquiatr,2012,70(1):59-66.
[46] Kageyama T,Komori M,Miyamoto K,et al.Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica[J].J Neurol,2013,260(2):627-634.
[47] Zheng X,Zhang X,Liu X,et al.Patient with neuromyelitis optica spectrum disorder combined with Sj gren’s syndrome relapse free following tacrolimus treatment[J].Intern Med,2014,53(20):2377-2380.
[48] Cree BA,Lamb S,Morgan K,et al.An open label study of the effects of rituximab in neuromyelitis optica[J].Neurology,2005,64(7):1270-1272.
[49] Capobianco M,Malucchi S,Di Sapio A,et al.Variable responses to rituximab treatment in neuromyelitis optica(Devic’s disease)[J].Neurol Sci,2007,28(4):209-211.
[50] Bedi GS,Brown AD,Delgado SR,et al.Impact of rituximab on relapse rate and disability in neuromyelitis optica[J].MULTIPLE SCLEROSIS JOURNAL,2011,17(10):1225-1230.
[51] Yang CS,Yang L,Li T,et al.Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica[J].Neurology,2013,81(8):710-713.
[52] Tolerability KE,Rituximab SO.MabThera[J].Cancer Treat Rev,2005,31(6):456-473.
[53] Uzawa A,Mori M,Sato Y,et al.CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse[J].J Neurol Neurosurg Psychiatry,2012,83(3):339-340.
[54] Ayzenberg I,Kleiter I,Schr der A,et al.Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy[J].JAMA Neurol,2013,70(3):394-397.
[55] Kieseier BC,St ve O,Dehmel T,et al.Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses[J].JAMA Neurol,2013,70(3):390-393.
[56] Ringelstein M,Ayzenberg I,Harmel J,et al.Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder[J].JAMA Neurol,2015,72(7):756-763.
[57] Zappia E,Casazza S,Pedemonte E,et al.Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy[J].Blood,2005,106(5):1755-1761.
[58] Yamout B,Hourani R,Salti H,et al.Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study[J].Multiple Sclerosis,2009,15(9):S142.
[59] Karussis D,Karageorgiou C,Vaknin-Dembinsky A,et al.Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis[J].Arch Neurol,2010,67(10):1187-1194.
[60] Tyndall A.EULAR stromal cell translational group.mesenchymal stem cells for multiple sclerosis:can we find the answer?[J].Mult Scler,2010,16(4):386.
[61] Greco R,Bondanza A,Vago L,et al.Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica[J].Ann Neurol,2014,75(3):447-453.
[62] Greco R,Bondanza A,Oliveira MC,et al.Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party[J].Multiple Sclerosis,2015,21(2):189-197.
[63] Okada K,Tsuji S,Tanaka K.Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica[J].Intern Med,2007,46(19):1671-1672.
[64] Tradtrantip L,Ratelade J,Zhang H,et al.Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody[J].Ann Neurol,2013,73(1):77-85.
[65] Tradtrantip L,Asavapanumas N,Verkman AS.Therapeutic cleavage of Anti-Aquaporin-4 autoantibody in neuromyelitis optica by an IgG-Selective proteinase[J].Mol Pharmacol,2013,83(6):1268-1275.
[66] Saadoun S,Waters P,Macdonald C,et al.Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain[J].Ann Neurol,2012,71(3):323-333.
[67] Papadopoulos MC,Bennett JL,Verkman AS.Treatment of neuromyelitis optica: state-of-the-art and emerging therapies[J].Nat Rev Neurol,2014,10(9):493-506.
[68] Tradtrantip L,Zhang H,Saadoun S,et al.Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica[J].Ann Neurol,2012,71(3):314-322.